The Commercialization Gap™

Mike Hull • September 9, 2026

Academic research and commercial development reward different outcomes. A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk. The distance between those two states is the Commercialization Gap™.

Why the Gap Exists

Academic programs are usually designed around scientific questions: Can an effect be demonstrated? Is a mechanism real? Is a hypothesis supported? Commercial programs must answer additional questions: Who needs the product? What would they pay for? What claims can be supported? What evidence would change adoption? How will the product be manufactured, regulated, reimbursed, and defended?


  • Publication evidence may not match regulatory evidence.
  • A technically elegant solution may not fit clinical workflow.
  • A broad platform story may not identify the first product.
  • Patent ownership may exist without a strong freedom-to-operate position.
  • Market size may look large while the reachable initial market is small.
  • Positive pilot data may not answer the question a strategic partner needs answered.

The Cost of Discovering the Gap Late

The later a team discovers a commercialization requirement, the more expensive it can be to correct. A study may need to be repeated with a different comparator. A diagnostic may need a different intended-use population. A device may need human-factors work that was not budgeted. A therapeutic may need additional CMC or translational evidence before a partner is willing to engage.

How to Close the Gap

Start with the future decision-maker and work backward. Identify who eventually must say yes—customer, clinician, payer, FDA reviewer, licensee, investor, strategic partner—and determine what evidence that person or organization will require.


Then design the next technical milestone to answer both a scientific question and a commercial question whenever possible.


  • Define the initial product and use case.
  • Interview customers and users before locking the development plan.
  • Map regulatory and reimbursement assumptions early.
  • Identify the next licensing or financing milestone.
  • Build studies that reduce specific commercial risks.

BYB Takeaway

The Commercialization Gap™ is rarely closed by adding a business plan after the research is finished. It is closed by deliberately shaping research and development around the decisions that must eventually be made.

BYB helps researchers and founders identify commercialization gaps before they become expensive.

How to Commercialize University Research

By Mike Hull • September 14, 2026
Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

What Is a Biotech Commercialization Plan?

By Mike Hull • September 13, 2026
It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.

How Much Validation Do You Need Before Raising Capital?

By Mike Hull • September 12, 2026
There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.

License Your Technology or Start a Biotech Company?

By Mike Hull • September 11, 2026
For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further.

The Bootstrap Score™

By Mike Hull • September 10, 2026
The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

The Valley of Dilution™

By Mike Hull • September 8, 2026
There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.

The Bootstrap Flywheel™

By Mike Hull • September 7, 2026
The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.

Biotech Funding Sequence: What Money Should You Raise First?

By Mike Hull • September 6, 2026
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.

When Should a Biotech Startup Raise Venture Capital?

By Mike Hull • September 5, 2026
Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.

What Is NIH TABA?

By Mike Hull • September 4, 2026
NIH Technical and Business Assistance—commonly called TABA—is designed to help SBIR and STTR recipients address product-development and commercialization needs that are often outside the core scientific aims of the award.